Low-dose interferon-alpha in stage-I multiple myeloma and in IgM monoclonal gammopathy
- Cite this article as:
- Eastern Cooperative Study Group on Monoclonal Gammopathies Ann Hematol (1992) 64: 123. doi:10.1007/BF01697398
- 16 Downloads
Interferon (IFN)-a can induce objective responses in advanced-stage multiple myeloma (MM) and can delay disease progression in patients responsive to chemotherapy. We studied the effects of low-dose (3 MU daily) human recombinant IFN-α 2b for 6–12 months in 29 consecutive cases of previously untreated, stablephase, early stage, monoclonal gammopathy (MG) (23 cases of stage I MM and six cases of IgM MG). In 25/29 patients, the disease remained stable throughout the study period. A major objective response was observed in one of five cases of IgA MG. Normal Ig levels increased in all five cases of IgA MG. A significant disease progression occurred in 2/29 cases during the 1-year study period. These data showed that the objective response rate of early-stage MG to low-dose IFN was low and suggested that further investigation should focus on IgA MG.